In This Article:
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.
Why Investors Should Pay Attention to This Value Stock
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.
Pediatrix Medical Group (MD)
Headquartered in Sunrise, FL, Pediatrix Medical Group, Inc. changed its corporate name from Mednax, effective Jul 1, 2022, to improve brand awareness. It continues trading under its current ticker symbol, MD.
MD sits at a Zacks Rank #1 (Strong Buy), holds a Value Style Score of A, and has a VGM Score of A. Compared to the Medical Services industry's P/E of 15X, shares of Pediatrix Medical Group are trading at a forward P/E of 8.8X. MD also has a PEG Ratio of 0.9, a Price/Cash Flow ratio of 7.7X, and a Price/Sales ratio of 0.6X.
Many value investors pay close attention to a company's earnings as well. For MD, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.08 to $1.55 per share for 2025. Per share MD boasts an average earnings surprise of 19.4%.
With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding MD to their portfolios.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pediatrix Medical Group, Inc. (MD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).